233 related articles for article (PubMed ID: 18845565)
1. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55.
Oka S; Toshida T; Maruyama K; Nakajima K; Yamashita A; Sugiura T
J Biochem; 2009 Jan; 145(1):13-20. PubMed ID: 18845565
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
[TBL] [Abstract][Full Text] [Related]
3. What is the natural ligand of GPR55?
Okuno T; Yokomizo T
J Biochem; 2011 May; 149(5):495-7. PubMed ID: 21324983
[TBL] [Abstract][Full Text] [Related]
4. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
[TBL] [Abstract][Full Text] [Related]
5. Identification of GPR55 as a lysophosphatidylinositol receptor.
Oka S; Nakajima K; Yamashita A; Kishimoto S; Sugiura T
Biochem Biophys Res Commun; 2007 Nov; 362(4):928-34. PubMed ID: 17765871
[TBL] [Abstract][Full Text] [Related]
6. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.
Henstridge CM; Balenga NA; Ford LA; Ross RA; Waldhoer M; Irving AJ
FASEB J; 2009 Jan; 23(1):183-93. PubMed ID: 18757503
[TBL] [Abstract][Full Text] [Related]
7. Generation of lysophosphatidylinositol by DDHD domain containing 1 (DDHD1): Possible involvement of phospholipase D/phosphatidic acid in the activation of DDHD1.
Yamashita A; Kumazawa T; Koga H; Suzuki N; Oka S; Sugiura T
Biochim Biophys Acta; 2010 Jul; 1801(7):711-20. PubMed ID: 20359546
[TBL] [Abstract][Full Text] [Related]
8. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
[TBL] [Abstract][Full Text] [Related]
9. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors.
Zhao P; Abood ME
Life Sci; 2013 Mar; 92(8-9):453-7. PubMed ID: 22820167
[TBL] [Abstract][Full Text] [Related]
10. Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors.
Imbernon M; Whyte L; Diaz-Arteaga A; Russell WR; Moreno NR; Vazquez MJ; Gonzalez CR; Díaz-Ruiz A; Lopez M; Malagón MM; Ross RA; Dieguez C; Nogueiras R
Mol Cell Endocrinol; 2014 Mar; 383(1-2):159-69. PubMed ID: 24378736
[TBL] [Abstract][Full Text] [Related]
11. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.
Piñeiro R; Maffucci T; Falasca M
Oncogene; 2011 Jan; 30(2):142-52. PubMed ID: 20838378
[TBL] [Abstract][Full Text] [Related]
12. Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning.
Mosca MG; Mangini M; Cioffi S; Barba P; Mariggiò S
Cell Commun Signal; 2021 Apr; 19(1):48. PubMed ID: 33902596
[TBL] [Abstract][Full Text] [Related]
13. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
[TBL] [Abstract][Full Text] [Related]
14. Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor.
Lingerfelt MA; Zhao P; Sharir HP; Hurst DP; Reggio PH; Abood ME
Biochemistry; 2017 Jan; 56(3):473-486. PubMed ID: 28005346
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidylinositol signalling: new wine from an old bottle.
Piñeiro R; Falasca M
Biochim Biophys Acta; 2012 Apr; 1821(4):694-705. PubMed ID: 22285325
[TBL] [Abstract][Full Text] [Related]
16. Role of the lysophosphatidylinositol/GPR55 axis in cancer.
Falasca M; Ferro R
Adv Biol Regul; 2016 Jan; 60():88-93. PubMed ID: 26588872
[TBL] [Abstract][Full Text] [Related]
17. Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55.
Kotsikorou E; Lynch DL; Abood ME; Reggio PH
Chem Phys Lipids; 2011 Feb; 164(2):131-43. PubMed ID: 21185816
[TBL] [Abstract][Full Text] [Related]
18. The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.
Zhou XL; Guo X; Song YP; Zhu CY; Zou W
Acta Pharmacol Sin; 2018 Mar; 39(3):459-471. PubMed ID: 29188802
[TBL] [Abstract][Full Text] [Related]
19. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship.
Ross RA
Trends Pharmacol Sci; 2011 May; 32(5):265-9. PubMed ID: 21367464
[TBL] [Abstract][Full Text] [Related]
20. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Nevalainen T; Irving AJ
Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
